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Netrin receptor DCC plays critical roles in many
cellular processes, including axonal outgrowth and
migration, angiogenesis, and apoptosis, but the
molecular basis of DCC-mediated signaling is largely
unclear. ERK2, a member of the MAPK family, is one
of the few proteins known to be involved in DCC-
mediated signaling. Here, we report that ERK2
directly interacts with DCC, and the ERK2-binding
region was mapped to the conserved intracellular
P1 domain of the receptor. The structure of ERK2 in
complex with the P1 domain of DCC reveals that
DCC contains a MAPK docking motif. The docking
of the P1 domain onto ERK2 physically positions
several phosphorylation sites of DCC in the vicinity
of the kinase active site. We further show that the
docking interaction between the P1 domain and
ERK2 is essential for the ERK2-mediated phosphor-
ylation of DCC. We conclude that DCC signaling is
directly coupled with MAPK signaling cascades.
INTRODUCTION
DCC (deleted in colorectal cancer), first isolated as a candidate
tumor-suppressor gene due to its frequent deletions in colorectal
cancers (Fearon et al., 1990), encodes a single transmembrane
protein which has subsequently been shown to be a netrin
receptor (Keino-Masu et al., 1996). The netrin/DCC signaling
pathway mediates axon outgrowth and guidance (Fazeli et al.,
1997; Keino-Masu et al., 1996; Kolodziej et al., 1996). DCC not
only mediates netrin-induced axon attraction but also partici-
pates in repulsive axon guidance together with UNC5, another
netrin receptor (Chan et al., 1996; Hong et al., 1999; Leonardo
et al., 1997). DCC is a type I transmembrane protein that
possesses immunoglobulin (Ig) repeats and fibronectin type III
(FNIII) repeats in its extracellular region. Its cytoplasmic domain
contains three conserved sequence motifs, named P1, P2, and
P3 (Kolodziej et al., 1996), although no well-defined structural1502 Structure 18, 1502–1511, November 10, 2010 ª2010 Elsevier Ldomains or catalytic activity have been identified thus far for
the DCC cytoplasmic domain. Both in vitro and in vivo studies
have demonstrated that the attractive response of DCC to
netrins specifically originates from the cytoplasmic domain of
the receptor, as a chimera DCC in which the extracellular portion
of DCC is fused with the cytoplasmic part of UNC5 elicited
repulsive responses to netrin (Hong et al., 1999; Keleman and
Dickson, 2001). Due to the lack of catalytic motifs in its intracel-
lular domain, DCC is thought to transmit its signal by binding to
its downstream proteins. Identification of DCC intracellular
domain binding partners has helped in understanding netrin/
DCC downstream signaling events. For example, FAK and Src
family kinase Fyn were identified to interact with the P3 domain
of DCC, and netrin stimulation induced tyrosine phosphorylation
of the receptor by both kinases (Li et al., 2004; Liu et al., 2004;
Rajasekharan et al., 2009; Ren et al., 2004). The disruption of
either FAK signaling or Src family kinase activity abolished
netrin-induced axon outgrowth and attractive growth cone
turning. Netrin stimulation of neurons has also been found to
induce DCC-dependent MAP kinase activation, which is essen-
tial for neurite outgrowth and directed axonmigrations (Campbell
and Holt, 2003; Forcet et al., 2002). Other proteins found to be
involved in netrin/DCC signaling include myosin X (Zhu et al.,
2007), Dock180 (Li et al., 2008), and PITPa (Xie et al., 2005). Inter-
estingly, essentially all known DCC-binding proteins bind to the
conserved P3 domain of DCC. It is worth noting that functional
studies have demonstrated that the conserved P1 and P2
domains are required for the axonal guidance activity of DCC
(Hong et al., 1999; Keleman and Dickson, 2001). Therefore, it is
predicted that there remain unidentified proteins capable of in-
teracting with the P1 and/or P2 regions of DCC.
Both DCC and UNC5 have also been shown to be intimately
linked to cell survival. It has been proposed that both DCC and
UNC5 function as dependence receptors for netrins. The
engagement of DCC and UNC5 with netrins promotes cell
survival, whereas the absence of netrins stimulates cell death
(Goldschneider and Mehlen, 2010; Llambi et al., 2001). The
downregulation of DCC and/or the upregulation of netrins
promotes cell survival and tumor formation (Arakawa, 2004;
Fitamant et al., 2008; Mazelin et al., 2004; Thiebault et al., 2003).
MAP kinases are evolutionarily conserved enzymes linking cell
surface receptors to intracellular regulatory targets. In the MAPKtd All rights reserved
Figure 1. Direct Interaction of DCC with ERK2
(A) Schematic diagram of the cytoplasmic domain organization of DCC. The short bar denotes the synthetic docking peptide to ERK2. The figure also shows five
potential ERK2 phosphorylation sites of DCC.
(B) Affinity chromatographic purification of proteins that associate with the DCC1120-1326 fragment from rat brain lysate. ‘‘CNBr ctr’’ stands for the control
purification using the CNBr-activated Sepharose beads without coupling of the DCC1120-1326 fragment. The figure shows the silver staining of the proteins eluted
with a buffer containing 2 and 4Murea, respectively. Themass spectroscopy analysis of the phosphorylation state of the pulled down ERK2 is shown in Figure S1.
(C) Pull-down experiments showing the direct interaction between DCC and ERK2. In the left panel, GST-tagged DCC1120-1326 was used to pull-down untagged
ERK2. In the right panel, MBP-tagged ERK2 was used to pull down untagged DCC1120-1326.
(D) Analytical gel-filtration chromatography showing that DCC1120-1326 binds to ERK2 with 1:1 stoichiometry (see also Figure S1).
Structure
Structure of the ERK2/DCC Complexsignaling pathway, three conserved kinases (MAPKKKK,
MAPKK, MAPK) are activated in series by extracellular stimuli
and regulate key cellular functions, including proliferation, differ-
entiation, migration, and apoptosis, and participate in a number
of disease states, including chronic inflammation and cancer
(Park et al., 2007). For example, the ERK1/2 (extracellular
signal-regulated 1/2)-MAP kinase pathway is well known to be
linked to a large percentage of human cancers, and tumorigen-
esis is typically associated with the activation of the ERK
signaling pathways (Downward, 2003; Hoshino et al., 1999).
Interestingly, the netrin/DCC-mediated axonal migration is
known to be linked to ERK1/2 activation (Campbell and Holt,
2003; Forcet et al., 2002), although the exact molecular basis
of the DCC-ERK1/2 connection is unclear. Nonetheless, the
functional connection of DCC and ERK1/2 fits well with the
dependence-receptor hypothesis of DCC.
Here, we report that DCC interacts directly with ERK2 through
its intracellular P1 domain. The crystal structure of inactive
ERK2 in complex with a DCC peptide reveals a docking motif-
mediated binding of DCC to ERK2. We discover that DCC is
a direct substrate of ERK2. We also show that the docking inter-
action is required for the phosphorylation of DCC by ERK2. Our
findings indicate that netrin/DCC-induced activation of ERK2Structure 18, 1502–151can directly regulate cellular signaling events of DCC via its
phosphorylation.
RESULTS
DCC Directly Interacts with ERK2
As the first step in understanding DCC-mediated signaling
events, we attempted to identify DCC-interacting proteins from
rat brains using affinity chromatography with various purified
intracellular DCC fragments as the bait. Purified proteins were
subjected to mass spectrometry analysis for identification.
Such affinity-based purification using the bait DCC1120-1326,
which includes the juxtamembrane region and the conserved
P1 domain of DCC (Figure 1A), identified ERK2 as a prominent
DCC binder (Figure 1B). Mass spectroscopy analysis
showed that the pulled down ERK2 is unphosphorylated
(see Figure S1 available online). Importantly, ERK2 was not
detected in parallel affinity purifications using DCC-P2&3
(1327–1445) and DCC-P3 (1374–1445) as baits (data not shown),
indicating that the association of DCC with ERK2 is specifically
mediated by the N-terminal part of the DCC intracellular domain.
We then examined the potential direct interaction between
DCC1120-1326 and ERK2 using in vitro pull-down assays. Purified1, November 10, 2010 ª2010 Elsevier Ltd All rights reserved 1503
Figure 2. Characterization of the Interaction between DCC and ERK2
(A) Summary diagram showing themapping of the ERK2 binding site on DCC. The data were derived from the pull-down and analytical gel-filtration assays shown
in Figures 1C and 1D. The qualitative bind strengths of various DCC fragments to ERK2 are categorized as strong (‘‘+++’’), medium (‘‘++’’), weak (‘‘+’’), and non-
detectable (‘‘’’). The open square indicates the deletion of 10 residue (1145–1154) from DCC that eliminated the ERK2/DCC interaction.
(B) Fluorescence polarization-basedmeasurement of the binding affinities of theWT and various point mutations of ERK2with the FITC-labeled DCCpeptide. For
clarity, only representative binding curves are shown in the figure.
(C) KD values of the bindings of ERK2 and its mutants with the DCC peptide derived from the fluorescence experiment (see also Figure S2).
Structure
Structure of the ERK2/DCC ComplexGST-DCC1120-1326 robustly pulled down untagged ERK2
(Figure 1C). Reciprocally, MBP-tagged ERK2 was shown to
interact with untagged DCC1120-1326 (Figure 1C). The specific
interaction between ERK2 and DCC1120-1326 was further verified
using analytical gel-filtration chromatography (Figure 1D). The
gel-filtration experiment indicates that ERK2 and DCC1120-1326
can form a 1:1 complex with a molecular mass of 75 kDa
(Figure 1D).
The P1 Domain of DCC Is Responsible
for Binding to ERK2
We next tried to map out the minimal ERK2 binding region of
DCC using the pull-down assay shown in Figure 1C. The entire
cytoplasmic tail of DCC, containing the P2 and P3 regions in
addition to the DCC1120-1326, displayed no observable differ-
ences from the DCC1120-1326 fragment in binding to ERK2.
Consistent with this observation, the DCC fragment containing
the P2 and P3 fragments only showed no detectable binding to
ERK2 (Figure 2A). We further divided DCC1120-1326 into two frag-
ments. The N-terminal fragment (residues 1120–1212) contains
the highly conserved P1 domain, while the sequence of the
C-terminal fragment (1212–1326) is less conserved. The pull-
down-based assay showed that the DCC1120-1212 fragment
displays prominent binding to ERK2, although the binding is
slightly weaker than that of the DCC1120-1326 fragment1504 Structure 18, 1502–1511, November 10, 2010 ª2010 Elsevier L(Figure 2A). Interestingly, the DCC1212-1326 fragment also
showed weak but consistently detectable binding to ERK2
(Figure 2A). Thus, we conclude that the cytoplasmic tail of
DCC contains two ERK2 binding sites, with the DCC1120-1212
fragment being the stronger site and the DCC1120-1326 fragment
the weaker site. The 1:1 stoichiometry of the ERK2/DCC
complex shown in the gel filtration column implies that the two
binding sites of one DCC molecule synergistically interact with
one ERK2, explaining the strong interaction between DCC and
ERK2 observed in the affinity-based purification and the
in vitro pull-down assay shown in Figure 1.
We quantified the binding affinity of the DCC1120-1212/ERK2
complex using ITC titration and obtained a Kd of 20.0 mM
(Figure S2). The highly conserved P1 domain has previously
been identified to be required for DCC to function properly
(Hong et al., 1999). We reasoned that the P1 domain might be
required for DCC to bind to ERK2. Indeed, the deletion of
a 10 residue peptide fragment containing the first six amino acids
of P1 domain plus the four amino acids preceding the P1 domain
(1145KDLRPPDLWI1154) completely abolished the binding of
DCC1120-1212 to ERK2 (Figure 2A). We further discovered that
a 27 residue synthetic peptide containing the P1 domain of
DCC (1139KRKGSQKDLRPPDLWIHHEEMEMKNIE1165, referred
to as the DCC peptide) displayed an ERK2 binding affinity equal
to that of the DCC1120-1212 fragment (Kd 17.0 mM)td All rights reserved
Figure 3. The Crystal Structure of the ERK2/DCC Peptide Complex
(A) Ribbon diagram of the ERK2/DCC peptide complex. The disordered region is shown in dotted line. The DCC peptide is shown in a stick-and-ball model.
The omit map calculated with a model without DCC peptide is contoured at 1.0 s. The two phosphorylation sites (Thr183 and Tyr185) in the activation loop
of ERK2 are also shown in the stick model.
(B) Sequence alignment of the DCC peptide with the selectedMAPK docking motif peptides. The hydrophobic residues in the ØA and ØB positions and the basic
residues upstream of the ‘‘ØA-X-ØB’’-motif are highlighted in red and blue, respectively. The protein names at the left are from which each docking sequence
resides, and the kinase names at the right stand for the MAPK to which each docking sequence binds.
(C) Surface representation of ERK2 in complexwith the DCCpeptide (in the stickmodel). The hydrophobic, positively charged, negatively charged and uncharged
polar residues are colored in yellow, blue, red, and white, respectively.
(D) Stereoview of the detailed interactions between the DCC peptide (golden) and the docking groove of ERK2 (pink). Dotted lines denote hydrogen bonds and
salt bridges.
Structure
Structure of the ERK2/DCC Complex(Figure 2B; Figure S1), indicating that this 27 residue synthetic
peptide contains all necessary elements (with respect to the
DCC1120-1212 fragment) for binding to ERK2.
Structure of the ERK2/pepDCC Complex
To elucidate the molecular basis of the DCC-ERK2 interaction,
we determined the crystal structure of catalytically inactive
ERK2 in complex with the DCC peptide at a resolution of
1.95 A˚. The structure of the ERK2/DCC peptide complex was
solved by molecular replacement using the inactive ERK2 struc-
ture (PDB code 1ERK) as the search model. Except for the few
residues in the activation loop (residues 174–178 and Lys201)
and several residues at the two termini, the entire length of
ERK2 was well resolved in the refined model of the ERK2/DCC
peptide complex (Figure 3A). Compared to ERK2, the electron
densities of the residues from the DCC peptide were relatively
weak. Nevertheless, we were able to clearly trace the electron
densities of the eight residues in the middle of the peptide
(1148RPPDLWIH1155) (Figure 3A), and this stretch of the DCC
peptide was shown to be essential for binding to ERK2 in
Figure 2A.Structure 18, 1502–151The structure of the ERK2/DCC peptide complex clearly
shows that the DCC peptide binds to the so-called ‘‘docking
motif-binding site’’ of ERK2 (Figure 3A), a mode conserved in
MAP kinases when binding to their substrates/regulatory
enzymes (Carvalho et al., 2006; Zhou et al., 2006). Amino acid
sequence analysis of the DCC peptide with the known MAPK
‘‘docking motifs’’ indeed reveals that the DCC peptide
(1148RPPDLWI1154) contains the signature ‘‘(K/R)1-2-X2-6-ØA-X-
ØB’’ sequence found in all MAPK ‘‘dockingmotifs’’ (Figure B), ex-
plaining the specific binding between DCC and ERK2 as well as
hinting at DCC as a potential direct substrate of ERK2. In the
ERK2/pepDCC complex, the DCC peptide adopts an extended
conformation and binds to the hydrophobic docking groove of
ERK2 (Figure 3C). Intramolecular interactions, including
a hydrogen bond between Arg11480Nh (prime denotes the resi-
dues from the DCC peptide) and the carbonyl oxygen of
Pro11490 and a bidentate salt bridge between Arg11480 and
Asp11510, stabilize the poly-proline helix II conformation of the
1148RPPD1151 segment of the DCC peptide and facilitate the
formation of two pairs of inter-DCC/ERK2 hydrogen bonds
(between the carbonyl of Pro11500 and the N3 of His123 side1, November 10, 2010 ª2010 Elsevier Ltd All rights reserved 1505
Figure 4. DCC Binding-Induced Conformational Changes of ERK2
(A) Comparison of the conformations of the different docking peptides in structures of the ERK2/DCC, Fus3/Far1, Fus3/Ste7, and ERK2/HePTP complexes. The
ØA and ØB and R/K residues are shown in the stick model.
(B) Superposition of the backbone structures of the inactive ERK2 and ERK2 in the ERK2/DCC peptide complex showing the overall structural similarity of the two
forms of ERK2 except for its activation loop.
(C) Superposition of the ERK2 structures in the inactive ERK2 (blue), the ERK2/DCC complex (pink), and the ERK2/HePTP complex (yellow) showing the confor-
mational changes of the activation loop ERK2 upon binding to its docking peptides.
Structure
Structure of the ERK2/DCC Complexchain and between the carbonyl of T158 and Arg11480Nh;
Figure 3D). The formation of the poly-proline helix II conformation
of the 1148RPPD1151 segment also physically positions the
hydrophobic side chain Pro11490 (the Pro residue 3 residues
upstream of ØA) into the edge of the hydrophobic pocket accom-
modating the ØA-X-ØB-motif (see below). The interaction
between the ØA-X-ØB sequence of DCC (
1152LWI1154) and
ERK2 is highly similar to those observed in MAP kinases in
complex with their respective docking motifs (Carvalho et al.,
2006; Zhou et al., 2006). The side chain of Leu11520 (ØA in the
ØA-X-ØB sequence) makes van der Waals contact with Leu113
in aD, Leu119 in aD-aE loop, Phe127 in aE, and Leu155 in b7
of ERK2. Ile11540 (ØB) interacts with the side chains of Thr108
in aD, Leu155 in b7, and Thr157 in b7-b8 loop (Figure 3D). Two
additional hydrogen bonds are formed between DCC and
ERK2 (between backbone carbonyl oxygens Trp11530 and
Gln117N3 and between the backbone amide of Leu11520 with
the backbone carbonyl of Thr157) (Figure 3D).
Structure-based sequence alignment analysis of the MAP
kinase docking peptides reveals that the DCC peptide most
resembles the Fus3 substrate Far1 peptide and the JNK inhibitor1506 Structure 18, 1502–1511, November 10, 2010 ª2010 Elsevier LJIP1 peptide, each sharing a conserved Pro 3 residues upstream
of the ØA-X-ØB-motifs (Figure 3B). This Pro residue in the Far1
peptide was considered responsible for the unique conformation
of the peptide, with respect to other peptides, in the structures of
the Fus3/peptide complexes (Remenyi et al., 2005). Comparison
of complex structures also showed that the conformation of the
DCCpeptide ismostsimilar to thoseof theFar1andJIP1peptides
in their respective kinase complex structures,with thePro atØA-3
occupying the same position on the MAPKs (Figure 4A).
Thepositively charged residue(s) in the (R/K)1-2-(X)2-6-ØA-X-ØB
dockingmotifs have been shown to be important for their binding
to someMAP kinases, including ERK2 (Chang et al., 2002; Gold-
smith et al., 2004). The DCC peptide also contains an Arg and
a Lys at the ØA-4 and ØA-6 positions, respectively (Figure 3B).
No direct charge-charge interactions occur between these two
residues from DCC and the negatively charged residues in the
CD site of ERK2 (Figure 4A). The formation of intramolecular
salt bridges between Arg11480 and Asp11510 restrain the side
chain of Arg11480 from extending toward the ERK2 CD site. The
electron density of Lys11510 is completely invisible, suggesting
that the interaction between this DCC Lys and the ERK2 CDtd All rights reserved
Structure
Structure of the ERK2/DCC Complexsite is also minimal. It has been shown that the basic residues of
theMEF2A/MKK3bpeptides in complexwith p38aare alsohighly
disordered (Park et al., 2007).Wedirectly tested the contributions
of the potential charge-charge interaction between the positively
charged residues of the DCCpeptide and the negatively charged
residues (Asp316, 319, and Glu320) in the CD site of ERK2 by
substituting Asp316&319 or Glu320 with Ala. Consistent with
the structural analysis, the single or double substitution mutation
of ERK2 only showed marginal decreases in binding to the DCC
peptide (Figures 2B and 2C). In contrast, mutations of the resi-
dues at the ØA-X-ØB-docking groove of ERK2 (Q117A, L155A,
H123A, and Q117A/H123A substitutions) caused more evident
decreases in binding to the DCC peptide (Figure 2C). These
observations are consistent with the structural analysis of the
complex, indicating that the hydrophobic and hydrogen bond
interactions at the docking groove are essential for binding while
the CD site interaction is less important.
Peptide Binding-Induced Conformational Changes
in the ERK2 Activation Loop
The previous structural studies of MAP kinases revealed that
docking motif peptide binding can induce local as well as long-
range conformational changes (Zhou et al., 2006). Similar to
the ERK2/HePTP complex, the overall structure of ERK2 in the
ERK2/DCC peptide complex resembles active ERK2 more
than inactive ERK2. Superimposing the complex structure with
inactive (Zhang et al., 1994) and active ERK2 (Canagarajah
et al., 1997) structures gives backbone root mean square devia-
tions (rmsd) of 2.0 and 1.6 A˚, respectively. The backbone rmsd
between the two ERK2 structures in the ERK2/DCC and ERK2/
HePTP complexes is 1.4 A˚, indicating high structural similarity
between the two ERK2 complexes. The binding of the DCC
peptide does not induce substantial conformational changes in
ERK2 except in the activation loop of the enzyme (Figure 4B).
Prior to the determination of the ERK2/DCC complex structure,
the activation loop of ERK2 was shown to adopt three distinct
conformations, corresponding to the inactive, active, and dock-
ing peptide-bound forms of the enzyme (Akella et al., 2008; Zhou
et al., 2006). In our structure, the conformation of the activation
loop is most similar to that of the ERK2/HePTP complex, but
also shows obvious differences (Figure 4C). As observed in the
ERK2/HePTP complex, the binding of the DCC peptide exposes
the dual phosphorylation sites in the activation loop (Thr183 and
Tyr185) from the buried state in the inactive enzyme to the fully
exposed state (Figure 4C). However, the side-chain orientations
of Thr183 and Tyr185 are quite different in the two complex
structures. Specifically, Tyr185 in ERK2/DCC forms a hydrogen
bond with the side chain of Arg170, a residue that interacts with
pT183 in active ERK2. Tyr185 in ERK2/HePTP points in the
opposite direction (Figure 4C). The side-chain orientations of
Tyr185 in both complexes significantly deviate from that in active
ERK2. These observations suggest that the activation loop is
intrinsically dynamic and subtly regulated both by docking inter-
actions and by phosphorylations.
ERK2 Directly Phosphorylates DCC
Given that DCC contains several ERK2 phosphorylation
motifs downstream of its kinase docking sequence (Figure 1A),
we hypothesized that DCC is likely to be a substrate of theStructure 18, 1502–151kinase. We tested this hypothesis by in vitro DCC phosphoryla-
tion assay. There are five potential phosphorylation sites in the
cytoplasmic domain of DCC (aa 1120–1445), three within the
DCC1120-1326 fragment and the other two in the P2 domain and
the P2/P3-linker region (Figure 1A). To map the individual ERK2
phosphorylation sites on DCC, we generated three DCC frag-
ments with increasing lengths (DCC1120-1212, DCC1120-1326, and
DCC1120-1445), and performed time-dependent in vitro phosphor-
ylation assays using MEK1-activated ERK2. ERK2-mediated
phosphorylation of DCC fragments can be conveniently moni-
tored by phosphorylation-induced mobility shifts of DCC bands
on SDS-PAGE (Figure 5). The DCC1120-1212 fragment contains
two potential ERK2-phosphorylation sites (Ser1178 and
Thr1187). Incubation of the DCC1120-1212 fragment with active
ERK2 resulted in two additional discrete bands of DCC with
slower mobility, with the upper band being phosphorylated
somewhat faster than the lower band, indicating that both
Ser1178 and Thr1187 are phosphorylated by ERK2 (Figure 5A).
Substitution of Ser1178with Ala specifically eliminated the upper
phosphor-DCC band (Figure 5A, middle panel), and substitution
of both Ser1178 and Thr1187with Ala completely abolishedDCC
phosphorylation byERK2. Thedata in Figure 5Aalso indicate that
the lower band represents the pT1187 form of the DCC fragment
and the upper band stands for the pS1178 (or the pS1178/
pT1187, thus the assignment of the phosphorylation state should
beconsidered tentative)DCC. Thephosphorylation ofS1178was
also confirmed by mass spectroscopy identification (Figure S3).
To determine whether S1267 might also be phosphorylated by
ERK2, we tested the DCC1120-1326 fragment. As expected, the
WT DCC1120-1326 can be efficiently phosphorylated by ERK2
(Figure 5B, middle). Clear phosphorylation of the DCC1120-1326
fragment with both Ser1178 and Thr1187 substituted with Ala
was observed (Figure 5B, left), indicating that Ser1267 can also
be phosphorylated by ERK2, albeit more slowly. Consistent
with this observation, the triple mutation (S1178A/T1187A/
S1267A) completely eliminated DCC1120-1326 phosphorylation
by ERK2 (Figure 5B, right). We then used the whole cytoplasmic
domain of DCC to identify whether the last two sites can be phos-
phorylated by ERK2. Again, the WT DCC1120-1445 shows clear
phosphorylation-induced mobility shifts. In contrast, the
S1178A/T1187A/S1267A mutant of DCC1120-1445 showed no
detectable mobility shift after prolonged incubation with active
ERK2 (Figure 5C). Therefore, we conclude that the last two pre-
dicted ERK2 phosphorylation sites (Thr1362 and Ser1390) are
not phosphorylated by ERK2, and that all the ERK2 phosphoryla-
tion sites onDCCare locatedwithin the linker betweenP1andP2.
Finally, we tested the role that the ERK2 docking sequence of
DCC plays in its phosphorylation by the kinase. We generated
a deletion mutant of DCC (DCC1120-1326D1145-1154), and the
mutant DCC was defective in binding to ERK2 (data not shown).
As shown in Figure 5D, DCC1120-1326D1145-1154 showed no
detectable phosphorylation by ERK2 even after incubation for
7 hr with the active kinase, indicating that the docking of DCC
to ERK2 is required for its phosphorylation by the kinase.
DISCUSSION
In this work, we confirm that DCC directly interacts with ERK2,
supporting the hypothesis that the netrin/DCC complex signaling1, November 10, 2010 ª2010 Elsevier Ltd All rights reserved 1507
Figure 5. ERK2 Directly Phosphorylates
DCC
(A) The DCC1120-1212 fragment phosphorylation by
ERK2 assayed by the time-dependent, phos-
phorylation-induced mobility shift of the DCC
fragments. The WT DCC1120-1212 displays two
additional bands with slower mobility after phos-
phorylation (indicated by arrow heads, left). The
substitution of Ser1178 with Ala eliminated the
top band observed in the WT protein (middle).
Mutation of both Ser1178 and Thr1187 completely
eliminated the phosphorylation-induced mobility
shift of DCC1120-1212 (right). The phosphorylation
of Ser1178 were further confirmed by the mass
spectroscopy analysis (Figure S3).
(B) The same strategy was used to identify the
third ERK2 phosphorylation site (Ser1267) of
DCC using the DCC1120-1326 fragment.
(C) No detectable phosphorylation of Ser1362 and
Ser1390 by ERK2 could be observed.
(D) The phosphorylation of DCC by ERK2 re-
quires the DCC docking sequence. The figure
shows that deletion of the docking sequence
(DCC1120-1326D1145-1154) completely abolished
its phosphorylation by ERK2 (see also Figure S3).
Structure
Structure of the ERK2/DCC Complexevents is directly coupled with the MAPK signaling pathways
(Yang et al., 2009). We further demonstrate that the conserved
P1 domain of DCC mediates its interaction with ERK2. The
crystal structure of the ERK2/DCC peptide complex reveals
that the ERK2-binding P1 domain of DCC contains a typical
docking sequence found in numerous MAPK substrates and
MAPK regulatory enzymes. Most importantly, we discover that
DCC is a direct substrate of ERK2. We show that the docking
motif-mediated ERK2 binding is absolutely required for ERK2
phosphorylation of three residues (Ser1178, Thr1187, and
Ser1267) in the cytoplasmic domain of DCC. This ERK2-medi-
ated phosphorylation of DCC is likely to be physiologically
relevant, as it has been shown that ERK2 can be activated by
the netrin/DCC complex and that the activated ERK2 can be re-
cruited to the DCC receptor complex (Campbell and Holt, 2003;
Forcet et al., 2002). The direct phosphorylation of DCC by ERK2
immediately suggests that, in addition to being an adaptor
serving to link the ERK1/2 signaling complexes, the cytoplasmic
domain of DCC actively participates in signaling events in an
ERK2 phosphorylation-dependent manner. One might envision
that the ERK2-mediated phosphorylation of one or more of the
three sites of DCC identified in this studymay serve as regulatory
switch(es) for DCC to interact with its downstream signaling
partners (e.g., the SH2 domains of NCK, (Li et al., 2002)). Another
possible function of ERK2-mediated phosphorylation of DCC
could be disrupting the interactions of DCC with its binding
partners, resulting in the downregulation of downstream
signaling. How ERK1/2 activation and ERK1/2-mediated phos-
phorylation of DCC relate to DCC’s direct downstream
processes, however, remains to be established. Nonetheless,
our findings strengthen the link between the ERK1/2 signaling1508 Structure 18, 1502–1511, November 10, 2010 ª2010 Elsevier Lpathway and netrin/DCC signaling events, and furthermore
uncover a potentially new ERK1/2 phosphorylation-dependent
DCC signaling mechanism. While this paper was in preparation,
a report by Tcherkezian et al. (2010) was published, showing
direct association of DCC with protein synthesis machinery for
axon growth and development and the P1 domain is essential
for this association. Interestingly, ERK2 was also identified to
associate with DCC in their proteomic study. Since ERK2 activity
is directly associated with protein synthesis via eIF2a (Monick
et al., 2006) and eIF4E (Herbert et al., 2002), this report together
with our study provides a strong link between ERK2 and DCC-
mediated protein synthesis.
Docking motif-mediated binding is common in interactions
between MAP kinases and their substrates or regulatory
enzymes (Goldsmith et al., 2007). The ERK2/DCC interaction
follows this common enzyme/substrate interaction mode. The
P1 domain-mediated docking of DCC onto ERK2 increases the
specificity and efficiency of the phosphorylation of DCC by
the kinase, and deletion of the docking motif completely
abolishes ERK2 phosphorylation of DCC even though the DCC
cytoplasmic tail with P1 deletion retains a weak ERK2 binding
capacity (Figure 2A). Our in vitro phosphorylation assay further
showed that the three phosphorylation sites on DCC showed
different phosphorylation efficiencies by ERK2 (in the decreasing
order of Ser1178, Thr1187, and Ser1267; Figure 5). The differen-
tial phosphorylation efficiencies of the three sites by ERK2 can
be nicely explained by the structure of the ERK2/DCC peptide
complex. Ser1178 is closest to the C-terminal end of the docking
motif and therefore is in the most favorable orientation to access
the active site of ERK2. In contrast, Ser1267 is more than 110
residues away from the docking sequence of DCC (the entiretd All rights reserved
Table 1. Statistics of X-ray Crystallographic Data Collection and
Model Refinement
Data collection
Space group P32
Unit cell parameters
a, b, c (A˚) a = b = 87.309, c = 94.721
Resolution range (A˚) 50.00–1.95 (1.98–1.95)
No. of unique reflections 30,642 (1538)
Redundancy 10.8 (10.6)
I/s 36.28 (3.59)
Completeness (%) 99.9 (100.0)
Rmerge (%)
a 6.6 (67.0)
Structure refinement
Resolution (A˚) 47.23–1.95 (2.00–1.95)
Rcryst/Rfree (%)
b 19.9 (27.2)/24.0 (30.1)
rmsd bonds (A˚)/angles (degree) 0.007/0.976
No. of reflections working set/test set 27547/1547
No. of atoms
Protein atom 2845
Water molecules 176
Others 6
Average B factor of protein/peptide(A˚2)c
Main chain 39.70/71.78
Side chain 42.57/79.03
Ramachandran plot
Most favored regions 90.90%
Additionally allowed 8.70%
Generously allowed 0.30%
Numbers in parentheses represent the value for the highest resolution
shell.
aRmerge =
P jIi  Imj=
P
Ii, where Ii is the intensity of measured reflection
and Im is the mean intensity of all symmetry related reflections.
bRcryst =
P jjFobsj  jFcalcjj=
P jFobsj, where Fobs and Fcalc are
observed and calculated structure factors. Rfree =
P
T jjFobsj  jFcalcjj=P
T jFobsj, where T is a test data set of about 5% of the total reflections
randomly chosen and set aside prior to refinement.
c B factors are calculated by combining the residual B factor and TLS
parameters using TLSANL program in CCP4.
Structure
Structure of the ERK2/DCC Complexcytoplasmic domain of DCC is essentially unstructured, our
unpublished data) and therefore is in the least favorable position
to be phosphorylated by ERK2. By the same logic, no phosphor-
ylation could be detected for the two predicted ERK2 phosphor-
ylation sites in the P2 (Thr1362) and the P2/P3-linker (Ser1390).
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The coding sequences of all DCC cytoplasmic constructs and mutants were
PCR amplified from rat DCC and cloned into a PET-32a vector. The wild-
type ERK2 and its mutants were cloned into PET-15b or PET-MBP.3C vectors
for expressing different tagged ERK2. Proteins were expressed in BL21
Escherichia coli cells. The His6-tagged proteins were purified using Ni
2+-NTA
agarose column followed by size-exclusion chromatography. The GST fusion
proteins were purified using GSH-Sepharose affinity chromatography.
The constitutively active MEK1 (R4F, DN3/S218E/S222E) and N-terminal
His6-tagged ERK2 were co-expressed in BL21 (DE3) E. coli cells with theStructure 18, 1502–151plasmid PET-His6ERK2/R4F (a generous gift from Dr. Melanie Cobb, Univer-
sity of Texas Southwestern Medical Center, Dallas). The active ERK2 was ex-
pressed and purified following the strategy described previously (Heise and
Cobb, 2006). The phosphorylation state of the purified, active ERK2 was veri-
fied by SDS-PAGE-based band shift and LC-ESI-MS/MS.
Affinity Purification with Rat Brain Lysate
Purified recombinant DCC fragments were individually coupled to CNBr-acti-
vated Sepharose beads following the manufacturer’s instruction (GE, health-
care). In brief, DCC proteins were dialyzed into 0.1 M NaHCO3 buffer (pH 8.3)
containing 0.5 M NaCl. Activated beads and DCC proteins were mixed and
shaken at room temperature for 1 hr. The remaining active groups on the beads
were quenched by incubating with 0.1 M Tris at pH 8.0. The DCC coupled
beads were first balanced with rat brain homogenate buffer (50 mM HEPES
[pH 7.4] containing 0.1 M NaCl, 10% glycerol, 1 mM dithiothreitol, 1 mM
EDTA, and the protease inhibitor cocktail from Roche) and then mixed with
the rat brain homogenate at 4Cwith shaking for 1 hr. After extensive washing,
the bound proteins were eluted step-wisely with elution buffer containing 2 M,
4M,6MUrea, and1%SDS, respectively. Theelutedproteinswereprecipitated
with TCA. After drying, the precipitated proteins were resolved by an 18 cm
8%–15% gradient SDS-PAGE and detected using silver staining.
Mass Spectroscopy
Protein bands from the silver-stained gels were excised and digested with
trypsin (Promega). The digested peptides were eluted with 0.1% TFA and
10% CAN and analyzed by a 4700 Proteomics Analysis mass spectrometer
(Applied Biosystems). If necessary, the eluted peptide were separated by
nanoLC and analyzed by an on-line LC-ESI-MS/MS. The MASCOT software
was used to search the MALDI-TOF MS data. The LC- ESI-MS/MS data was
analyzed using TurboSequest V. 27.
In Vitro Pull-Down Assay
Equal molar amount of GST and GST-fused DCC proteins (3.7 nmol each)
were loaded onto 20 ml of GSH-Sepharose 4B slurry beads (GE, HealthCare)
in an assay buffer containing 50 mM Tris-HCl (pH 8.0), 100 mM NaCl, 1 mM
EDTA, 1 mM DTT, and protease inhibitors. The protein loaded beads were
then mixed with purified potential binders individually. After incubation for
3 hr at 4C, and the beads were washed three times each with 500 ml of assay
buffer. The proteins captured byGSH-Sepharose beadswere eluted by boiling
with the SDS-PAGE sample buffer and resolved and detected by 15% SDS-
PAGE using Coomassie blue staining. In vitro MBP-tagged protein pull-
down assay was carried out with the amylase magnetic beads (NEB) following
the similar protocol as that described for the GSH-Sepharose pull-down
experiment above.
Fluorescence Polarization Assay
Fluorescence polarization-based titration assays were performed on a Perki-
nElmer LS-55 fluorimeter equipped with an automated polarization at room
temperature. Commercially synthesizedDCCpeptidewas labeledwith fuores-
cein-5-isothiocyanate (Invitrogen, Molecular Probe) at its N terminus. The
labeled peptide was purified by passing through a Superdex Peptide
10/300GL column (GE, HealthCare) in the assay buffer (50 mM Tris-HCl
[pH 8.0], 100 mM NaCl, 1 mM EDTA, and 1 mM DTT). The fluorescence polar-
ization values of the FITC-labeled DCC peptide (1 mM) were recorded with
increasing amount of ERK2 or its mutants. The dissociation constant (Kd)
was calculated by fitting the classical one binding site model.
Kinase Assay
About 1 mg/ml DCC fragments were dialyzed in the phosphorylation reaction
buffer containing 20mMTris (pH 8.0), 10mMMgCl2, 100mMNaCl, 2mMDTT,
and protease inhibitors at 30C (Canagarajah et al., 1997; Yang et al., 2007).
The concentration of active Erk2 and ATP were kept at 1 mg/ml and 0.1 mM,
respectively. The reaction at each desired time point was stopped by boiling
the assay mixtures with the SDS-PAGE sample buffer.
Crystallography
Crystal of ERK2 in complex with the DCC peptide was obtained by the hanging
drop vapor diffusion method at 20C. The DCC peptide (residues 1140–1166)1, November 10, 2010 ª2010 Elsevier Ltd All rights reserved 1509
Structure
Structure of the ERK2/DCC Complexwas commercially synthesized and purified by HPLC. Fresh purified ERK2was
concentrated to 9 mg/ml before saturating amount of the DCC peptide was
added. The EER2/DCC complex crystals were obtained by mixing 1 ml of the
complex with 1 ml buffer composed of 0.1 M HEPES (pH 6.9), 18%
PEG3350, and 0.12 M KSCN.
The structure of the EER2/DCC complex was solve by the molecular
replacement using the inactive ERK2 structure (PDB code 1ERK) as the search
model with PHASER (Storoni et al., 2004). The initial model was rebuilt manu-
ally and then refined using REFMAC (Murshudov et al., 1997) against the 1.95 A˚
resolution data set. Further manual model building and adjustment were
completed using COOT (Emsley and Cowtan, 2004). In the final stage, the
TLS refinement was applied. TLS groups are determined by TLSMD server
(http://skuld.bmsc.washington.edu/tlsmd/index.html). The stereo-chemical
quality of the final model was validated by PROCHECK (Laskowski et al.,
1993). The final refinement statistics are listed in Table 1. The structure figures
were prepared using the program PyMOL (http://pymol.sourceforge.net/).ACCESSION NUMBERS
Coordinates for the ERK2-DCC peptide complex have been deposited in the
Protein Data Bank (PDB accession number 3O71).SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and can be found with this
article online at doi:10.1016/j.str.2010.08.011.
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